Good Lifestyle

For those who have prescribed them, anticoagulants can be one of the most essential pills of a person's daily diet. Drugs can help patients with a higher risk of stroke or potentially serious health events caused by blood clots remain healthy. Like any other pills we take , anticoagulants come with their own inherent risks - namely, they can make someone bleed in the case of an accident. But now, the Food & Drug Administration (FDA) warns that a relatively current blood diluent has been recalled due to "impurity". Read the rest to find out if you risk potentially serious health problems.

Read this then: 2.5 million pounds of meat recalled on contamination fears, USDA warns .

On March 22, the FDA announced that New Jersey LLC Laboratories Ascend had voluntarily recalled his dabigatran capsules, etc., drug drugs. The articles affected were sold in doses of 75 mg and 150 mg in plastic bottles of 60 accounts. AE0FCC31AE342FD3A1346EBB1F342FCB

According to the alert, the drug is prescribed as an oral anticoagulant to "reduce the risk of stroke and blood clots". The affected product was distributed to wholesalers and retailers of the country in the United States from June 2022 to October 2022. The articles recalled can be identified by the NDC, the lot number and the expiration date printed on the bottle, which are all listed in the agency's notice.

The Liberation of the FDA stipulates that the Laboratories asserts the market medication due to the presence of nitrosamine impurity - in particular the n -nitrosodimethylamine - by climbing above the acceptable daily (ADI) levels (ADI) the entire FDA.

Depending on the opinion, "everyone is exposed to a certain level of nitrosamines", which can be found in water and foods such as dried and toasted meats, dairy products and vegetables. However, exposure to higher quantities over longer periods may increase the risk of cancer in people. THE National Health Institutes (NIH) awarded the N-Nitrosodimethylamine Safety labels "Acute toxin", "Health Risk" and "Environmental Danger".

In relation: For more information, register for our daily newsletter .

The opinion of the FDA indicates that there has been no report of unfavorable health events linked to the recalled blood lighting. The company asks pharmacies and distributors to "stop use and distribution and in quarantine the product immediately".

Anyone who already has the product affected in his pharmacy cabinet is advisable to continue taking your medication for the moment and calling your doctor or health care provider to discuss alternative treatment. Those who believe they have experienced health problems or other problems due to the recalled blood reduction should immediately contact their doctor.

Consumers with questions about the recall can contact Laboratories at any time by calling the hotline indicated in the agency's advice. They can also use it to report any adverse event or other products of product quality.

Whether free or prescribed, people should feel convinced that the drugs they use are safe as long as they are used correctly. But similar to food and drinks, they can always be subject to the same types of health risk reminders used to ensure public safety - and there are some recent examples.

On February 1, the FDA announced that IBSA Pharma Inc. had published a voluntary reminder for 27 lots of his medication in oral soil solution (levothyroxine sodium), which is generally prescribed to treat hypothyroidism. The company said that it had drawn the affected product after discovering that the prizes in question could be lower that listed on its packaging. Sub-powerful prescription drugs could then cause hypothyroidism in patients.

On February 24, the FDA announced that Global Pharma Healthcare had voluntarily recalled part of its artificial ointment distributed by Delsam Pharma "Due to a possible microbial contamination." The recall came a few weeks after the company fired 10 different brands from Artificial tears eye drops Following a joint survey of the FDA and the Centers for Disease Control and Prevention (CDC) which connected the products to a strain "largely resistant to medication" by Pseudomonas aeruginosa bacteria. As of March 22, there was 68 infections reported Linked to articles, including eight who had lost their vision and three who died, reported CBS News.

And on March 16, the U.S. Product Safety Commission (CPSC) alerted the public that Pfizer Inc. had published a reminder of his drugs in Rimegepant - sold the Nurtec ODT brand - prescribed to patients for the Migraine treatment . The move specifically affected the oral disintegration tablets sold in dose blister packs from 75 mg to 8 units. In this case, the medication was drawn because it was not sold in the children's resistant packaging required by law, creating a potentially serious risk of poisoning.